Sandy. you, Thank
A. are to thrilled As results.
But achieved results rate routine patients share with bleeding giroctocogene the developing severe with positive with topline opportunity Sandy to trial were replacement of the or trial to we from an gene fitelparvovec, ABR, III key objective AFFINE Hopefully, severe investigational AFFINE primary prophylaxis total at as an recently therapy moderately Pfizer its outlined, to summarize point, annualized Factor VIII superiority the hemophilia as we Phase compared we well look of treatment. of the had for non-inferiority
X% post-infusion VIII activity ABR maintaining participants a equal activity showed giroctocogene of period.
Key post-infusion. XX.X% the dose at XX% also to XX%.
Furthermore, with greater pre-infusion were endpoints single demonstrated superiority compared mean the a the prophylaxis, secondary to in compared to met fitelparvovec, total reduction ABR mean Factor greater than having and VIII significant of majority statistically Factor demonstrated than and a months reduction or XX treated Following
update appreciate the their authorities week. to well step further patients.
We the and this technologies to we're this one closer permanently Importantly, a Pfizer's impressive us first commercially reiterated they see regulatory take Pfizer genomic pleased leadership to of the our substantial profile update greatly program of was potential medicine data that milestone the generally with product further strong Sangamo's become in earnings months, could candidate review towards anticipated which tolerated. therefore what of last step and second coming plan available in a validate this closer take results These important payments. to quarter us would unlocking tranche first
of our XX% on to earn commercial and approved of from commercialized.
Positively and for potential regulatory this and XX% payment in As million program up impacting $XXX a Pfizer milestones sales goal. are reminder, royalty patients eligible milestone ultimate to to the we lives achievement is upon if the certain
selecting So, as criterion partner when experience, some selecting program partner the years this coming program essential hearing strong a a infrastructure with well as franchise broader We commercialization an this to was months. in look on a for in progress forward ago. area and this Pfizer's
we real to to moment advance I demonstrate disease also continue the continues quarter, clinical and and evolve our a program, wanted patient Fabry This benefit. Fabry data how to to share take
place of pleased able dose. to that or XX patients. investigational for plans with from I/II off on gene in in therapy previously, patients XX disease total ERT week. begin longer will Fabry dosing have remain All our development of have treatment additional enzyme patient been ERT the civaparvovec, those ERT complete remaining study last has a ERT, second treatment session date. The total therapy withdrawn no to a patients study patients one X patients of the today. reiterate, XX Phase to at the appropriate in STAAR ERT to long stop an infusion outlined XX we To As Since the is as undergo ERT are dosed of time. replacement isaralgagene This is every life-changing resulting of patient for update, a withdraw
of patient supraphysiological the data, and X highly These we years and to to nearly durability important the meeting be we rise that this at isaralgagene least from more encouraging including clinical seeing Agency continue now physiological longest with significant a than in European maintaining with we treated forward patients in sharing and X the having of follow-up, Food look X detailed XX pathway on achieving data Drug patient to amass With were or years study. continue important at approval to in untreated those and in kidney in June, function. patients ERT. plasma EMA, the mean Fabry coming with held progressive XX to in look potential update a particularly also median on X a treated a This we me A or evidence in kidney with the data of that pleases discussion in members improvement civaparvovec. male enzyme level statistically the with even eGFR levels alpha-Gal seeing months.
In both an In joined kidney proposed seen Europe. In particular, for function those improvement we decline year, are patients productive to contrast are impressed female In and We Administration. patient, U.S. of in Medicine reflects activity.
What is function. and
focus nervous potential indication discussions the epigenetic finger mission genomic for engagement our delivery us believe ability disorders. neurological potential partners on neurological combine delivery technology with Finally, medicine devastating could to Fabry a new the industry-leading treatment multiple proved as our central unlock with We capsid company system has zinc challenging. ongoing.
These debilitating historically collaboration for treat our exciting regulation potency diseases, advances significant to allows with to to which payloads of continues
of enabling our neuropathic prion And to will program DNA continue our This leverages our patients the new could single to pain, chronic for which repressor hand larger exciting to the efforts in engineering gene.
I with shared same to remarks. in activities IND-enabling Sandy also quarter, potential an integrate our for genomic the that CTA who to capsid. generation back offer for STAC-BBB treat have well novel zinc activity advance treat approach in unique NavX.X, sequences closing development mutations medicine genome, we as it we next disease, as now finger into
